Rank 2003, 2004 and 2005
Drug name sales drug name sales drug name sales.
1 Lipitor 9.23 Lipitor 10.86 Lipitor 12. 19
2 Zocor 5 POLIVE 5.64 POLIVE 6.2 1
3 Ogastrol/Prevaric acid 4.7 1 Zoco 5.20 Suletide /Advair 5.34
4 luohuoxi 4.34 seretide /Advair 4.74 luohuoxi 4.7 1
5 Zaipule 4.28 Huoxi 4.46 Naixin 4.63
6 Polivik 4. 13 Zyple 4.42 Zoco 4.4
7 erypo (EPREX/Procrit) 3.98 ogastro/prevacid4.14 Zaipule 4.2
8 seretide/advair 3.94 nexium 3.88 ogastro/prevacid4
9 Naixin 3.3 erypo (EPREX/Procrit) 3.59 Pravachol 3.82
10 zoloft 3. 12 risperidone 3.05 diovan/compound diovan 3.7
Total 46.03 total 49.99 total 53.2
It accounts for 9.36%, 9.09% and 9. 13% of the current market.
Sales list of the best-selling drugs in the world in 2008
Global market: downward curve
According to IMS Health, the global pharmaceutical market (by value) increased by 4.8% in 2008, reaching $773 billion (see figure 1 and figure 2). Although the global drug sales continued to grow in 2008, the growth rate has slowed down from the recent high of 10.2% in 2003 to 4.8% in 2008 (see figure 1). This trend reflects that the growth rate of the global pharmaceutical market has declined for the fifth consecutive year (see figure 1).
As for 2009, IMS predicts that the value of the global pharmaceutical market will only increase by 2.5%~3.5% at the fixed dollar exchange rate, reaching $750 billion (at the current market dollar price). This is the forecast made by IMS as of April 2009. Due to the low growth rate and the fluctuation of currency exchange rate, it is estimated that the global drug sales will decrease by 70 billion US dollars in 2008-2009. Among them,1500 million dollars is due to the weak economy and slow growth; The remaining $55 billion is based on the currency exchange rate impact of the Economist Intelligence Unit data. The short-term prospect of the global pharmaceutical market has improved, because the compound annual growth rate (CAGR) of this market is expected to be around 3%~6% from now to 20 13 years.
American market: hitting a record low
The United States is the largest drug market in the world. In 2008, American pharmaceutical sales only increased by 1.3%, reaching $29 1 billion. According to IMS company's forecast as of April 2009, in 2009, drug sales in the United States will drop by 65,438+0% ~ 2%, a record low, and CAGR is expected to be flat in the next five years. 20 1 1 The loss of patent protection for several blockbuster drugs will reduce the growth rate of the American pharmaceutical market until the end of 20 13.
Generic drugs: the growth rate slows down
The increase in the market penetration rate of generic drugs and the resulting decline in drug sales are the main factors that slow down the value growth of the American pharmaceutical market. According to the data provided by IMS, in the 12 months up to September 2008, the market value of generic drugs in the United States was $33 billion, and its sales accounted for 63.7% of the total sales in the American pharmaceutical market. Due to fierce competition, price pressure and the small number of "blockbusters" that lost patent protection in 2008, the sales of generic drugs in the United States increased by 5.4% and the growth rate decreased by 2.7% in the 12 months up to September 2008. In 2008, the growth rate of the global generic drug market also slowed down. In the 12 months to September 2008, the global sales of generic drugs increased by 3.6%, reaching $78 billion, which was significantly lower than the growth rate of 1 1.4% in the same period of 2007.
Product mix changes: biotech drugs continue to climb
Datamonitor, a market research and consulting organization, said that due to the intensified competition of generic drugs, the number of drugs in New Chemical Entities (NCEs) decreased and the NCEs return rate decreased. It is estimated that the sales of prescription drugs of large pharmaceutical companies will increase from $366.6 billion in 2007 to $407 billion in 20 13 years, and its CAGR is only expected to be 1.8%. While the sales of small molecule drugs are under heavy pressure, the sales of biotechnology drugs of large pharmaceutical companies are expected to continue to climb. By 20 13, biotech drugs are expected to account for 20% of prescription drug sales of large pharmaceutical companies. At the same time, by 20 13, the sales of its core products are expected to drop by nearly 50% to $47 billion.
In contrast, although the market size of medium-sized pharmaceutical companies and biotechnology companies is much smaller, the CAGR of prescription drug sales of these companies is expected to be stronger. Among them, the sales of medium-sized pharmaceutical companies will increase from $44 billion in 2007 to $62.9 billion in 20 13, and its CAGR is expected to be around 6. 1%. Small molecule drugs will continue to dominate the income of medium-sized pharmaceutical companies, and their sales share of prescription drugs will reach 92% by 20 13.
The sales of biotechnology companies are expected to increase from $34.6 billion in 2007 to $48 billion in 20 13, and its CAGR will reach 5.6%. In 2007, biotech drugs accounted for more than 50% of the sales of biotech companies. It is predicted that by 20 13 years, therapeutic proteins will account for nearly 70% of sales.
Ranking: The ranking of the best-selling drugs is mixed.
In 2008, the sales of 15 best-selling products reached $89 billion, accounting for 12% of the global pharmaceutical market. Just like in 2007, Lipitor/Atorvastatin of Pfizer won the sales champion again in 2008, with sales close to $ 654.38+0.37 billion (see table 654.38+0). Lipitor has also become the king of the American pharmaceutical market, with sales reaching $7.8 billion (see Table 2). However, great changes will take place in 20 1 1 year. Lipitor's American patent will expire soon, and this best-selling drug will be invaded by generic drugs. In order to cope with the sales hole left by Lipitor's loss of patent protection, Pfizer has taken a series of measures, including the acquisition of Wyeth for $68 billion. In 2007 and 2008, Lipitor accounted for more than 28% of Pfizer's total sales of prescription drugs.
Rookie: Lovenox (enoxaparin) of Sanofi-Aventis ranks 10, and Remicade (infliximab) ranks 8 th, the latter is produced and sold by Johnson & Johnson, Schering-Plough and Mitsubishi Tanabe Pharmaceutical Company of Japan.
Abandoned Children: Two other drugs fell out of the top ten list. Risperdal, the seventh drug for Johnson & Johnson in 2007, and darbepoetin alfa, the tenth drug for Amgen, did not appear in the top ten list in 2008.
Grand Slam: 65,438+00 products appeared in both the best-selling 15 drugs in the world and the best-selling 15 drugs in the US market. They are Venlafaxine from Wyeth; Enli of Amgen, Wyeth and Takeda Pharmaceutical Company (Inaxip); Lipitor; AstraZeneca Naisim (Esso Mprazole); Bristol-Myers Squibb and Sanofi-Aventis Polivi (clopidogrel); Remicade Seretide/Advair Disus; From GlaxoSmithKline; Seroquel from AstraZeneca (Quetiapine); Shunerning of Merck (Montelukast) and Takepron/Prevacid of Takeda Pharmaceutical Company (Lansoprazole) (see table 1 and table 2).
Leading: Five products have entered the top 15 of the best-selling drugs in the world, but they have not appeared in the top 15 of the best-selling drugs in the US market. These products are Genentech and Avastin (bevacizumab) from Roche; Abbott and Humera of Cai Wei (adalimumab); Lovenox from Sanofi-Aventis (enoxaparin); Genentech, Roche, Rituximab from Takeda, zyprexa (olanzapine) from Lilly.
In addition, there are five of the best-selling 15 drugs in the United States, but they did not appear in the list of the best-selling 15 drugs in the world in 2008. These products are aripiprazole from Bristol-Myers Squibb; Actos (Pioglitzone) of Takeda; Epoetin alfa from Amgen; Lexapro of Forest Laboratories and Neurasta of Amgen.
Product innovation has rebounded.
The level of product innovation is measured by the Center for Drug Evaluation and Research (CDER) of US Food and Drug Administration according to the number of new molecular entities (NMEs) approved by drugs and new biological products (BLAs). Compared with 2007, the level of innovation in 2008 has improved. In 2008, CDER approved 24 new drugs, of which 265,438+0 were drugs with ineffective market demand and 3 were BLAs. 24 new drugs were approved, hitting a new high in recent years. In 2007, 2006 and 2005, CDER approved 19( 17 NMEs and 2bras), 22( 18 NMEs and 4bras) and 20 (18 NMEs and 2bras) respectively. According to the data provided by FDA, the largest number of new drugs approved in recent years was in 2004, and CDER approved 36 new drugs (365,438+0 nmes, 5 BLAs).
Cenozoic era: In the first six months of 2009, CDER approved 65,438+02 new drugs (8 NMEs and 4 BLAs). The approved NMEs are Afinitor (everolimus) and Coartem (artemether and benflumetol) of Novartis; Bessie Vance of Bosch & Lomb Company (Bessie Fofloxacin); Fanapt of Zhonglian Pharmaceutical Company; Samska (Tovaputan); Otsuka American Pharmaceutical Company of Japan; Safella (Milnacipran) of Cypress Biological Sciences and Forest Laboratory; Ulefia (benzyl alcohol) from Scielle Pharmaceutical Company; Uloric(febuxostat) in Takeda. The approved BLAs is Dysport (Abobotulinumtoxina) of France Ispen Company; Ilaris of Novartis (Kanakinuba); Golimumab of Johnson & Johnson, etc.
Biotechnology drugs account for half of the country.
A major change in the pharmaceutical market is that biotech drugs are on the rise among the best-selling prescription drugs. According to the market compilation data provided by market research organization Evaluate Pharma, in 2000, among the top ten best-selling drugs in the world, only Epogen from Amgen and Procrit from Johnson & Johnson were biotechnological drugs. In 2008, five biotechnology products (Avastin, Enbrel, Epogen/proclit, Remicade and Rituxan) were listed as the top ten best-selling drugs by Evaluate Pharma. Evaluate Pharma predicts that by 20 14, the six best-selling drugs in the world will be biotechnology drugs, namely Avastin, Enlil, Humira, Rituxan, Sanofi-Aventis Lantus (insulin glargine) and Roche Herceptin (trastuzumab), and Remicade will occupy the ninth place in this list. This means that seven of the best-selling 10 drugs in the world will be biotechnological drugs.
Evaluate Pharma predicts that in 20 14 years, among the best-selling drugs in 100, the proportion of biotechnological drugs will exceed 50%, while in 2008 and 2000, it was only 28% and 1 1% respectively.